Translational Research in Oncology: The Need of Additional In Vitro Preclinical Testing Methods for New Drugs

Title:Translational Research in Oncology: The Need of Additional In Vitro Preclinical Testing Methods for New Drugs

Volume: 18 Issue: 23

Author(s): Theodore L. Drell IV, Kurt S. Zanker and Frank Entschladen

Affiliation:

Keywords: Cell migration, drug screening, invasion, in vitro assays, metastasis, translational oncology, cancer, cytotoxicity, cellular growth inhibition, angiogenesis

Abstract: Cancer remains one of the leading causes of death in the Western world. Despite bold advances in therapeutic oncology, new drug development is infamously ineffective due to the lack of predictive in vitro models. Most patients that suffer from cancer do not die from the primary tumor but due to the development of metastases. And yet current in vitro screening methods for new drugs in oncology still largely target cytotoxicity or the inhibition of cell growth, in which a potential anti-metastatic activity cannot be assessed. Herein the current in vitro models in oncology are reviewed and a new rationale for the pre-clinical development of specific, anti-metastatic therapeutic agents is introduced.

Cite this article as:

L. Drell IV Theodore, S. Zanker Kurt and Entschladen Frank, Translational Research in Oncology: The Need of Additional In Vitro Preclinical Testing Methods for New Drugs, Current Pharmaceutical Design 2012; 18(23) . https://dx.doi.org/10.2174/138161212801227069